NCT02746952View on ClinicalTrials.gov

Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2016

Primary Completion Date

July 28, 2020

Study Completion Date

July 28, 2020

Conditions

B-cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

UCART19

Trial Locations (9)

19104

Hospital of the University of Pennsylvania, Philadelphia

75010

Hôpital Saint-Louis, Paris

75571

Hôpital Saint-Antoine, Paris

77030

University of Texas MD Anderson Cancer Center, Houston

02114

Massachusetts General Hospital, Boston

812-8582

Kyushyu University Hospital, Fukuoka

060-8648

Hokkaido University Hospital, Sapporo

SE5 9RS

King's College Hospital NHS Foundation Trust, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

All Listed Sponsors

collaborator

ADIR, a Servier Group company

INDUSTRY

lead

Institut de Recherches Internationales Servier

OTHER

NCT02746952 - Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia | Biotech Hunter | Biotech Hunter